Rezolute Reports Second Quarter Fiscal 2024 Results and Provides Business Update tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.
13.02.2024 - Phase 3 clinical study of RZ358 underway in patients with congenital hyperinsulinism (cHI); topline results expected in mid-2025 Benefit shown in individual patient cases with RZ358 for tumor-associated hyperinsulinism (taHI) under Expanded Access .
REDWOOD CITY, Calif., Jan. 24, 2024 Rezolute, Inc. , a clinical-stage biopharmaceutical company committed to developing novel, transformative therapies for serious metabolic and rare.
Operator: Good day, and welcome to the Envelope Enterprise Holdings Second Half and Fiscal Year 2022 Earnings Conference Call. Please note, this event is being recorded.